TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of chronic hepatitis C.~* Liver biopsy performed within 2 years of Day 0 or during screening.~* Infected with hepatitis C virus genotype 2/3.~* Interferon alfa treatment naïve (ie, have never been treated with an interferon product).~* Subjects are eligible to enter the study if they (or their partners) are not pregnant or nursing, are sterile, or of non childbearing potential, or are willing to practice abstinence or use appropriate birth control methods during the study and for 7 months after the last dose of ribavirin.~* Have compensated liver disease.~Key Exclusion Criteria:~* Decompensated liver disease including those subjects with a past history or presence of ascites, bleeding varices or hepatic encephalopathy.~* History of moderate, severe or uncontrolled psychiatric disease, especially depression, including a history of hospitalization or prior suicidal attempt.~* Positive for human immunodeficiency virus (HIV-1) or hepatitis B surface antigen (HBsAG).~* Clinical diagnosis of other causes of chronic liver disease including but not limited to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, hemochromatosis, Wilson's Disease, or alpha 1-antitrypsin deficiency.~* A history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus).~* Active seizure disorder within the last 2 years.~* Organ transplant other than cornea and hair transplant.~* Clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia).~* Cancer within the last 5 years(with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix).~* Drug or alcohol addiction within the last 6 months. Subjects in a supervised methadone treatment program may be enrolled in the study.~* Received any experimental agent within 28 days prior to Day 0.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 900 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
- 2 (Type: EXPERIMENTAL): 1200 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
- 3 (Type: ACTIVE_COMPARATOR): 180 mcg PEG-IFNx2a every 1 week (24 doses)+ Ribavirin 800 micrograms per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of laryngeal cancer with intention to treat by radiotherapy using a 16 fraction 3 week scheme~  * Stage I or II~* No known CNS disease~PATIENT CHARACTERISTICS:~Age:~* 20 to 80~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Hepatic function normal~Renal:~* Renal function normal~Other:~* Not pregnant or nursing~* No serious active infection requiring antibiotic therapy~* No autoimmune disease~* No known seizures~* No psychosocial factors that would preclude study compliance~* No allergies to sargramostim (GM-CSF)~* Willingness to cooperate for regular mirror examination of the larynx~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy~Chemotherapy:~* No concurrent chemotherapy~Endocrine therapy:~* No prior or concurrent corticosteroids~* No concurrent hormonal therapy~Radiotherapy:~* See Disease Characteristics~Surgery:~* No major organ allografts~Other:~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Male and female, ages 18 to 70 years~* Diagnosis of plaque psoriasis for 6 months~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy~* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the study drug plus 90 days.~Exclusion Criteria:~* Any significant acute or chronic medical illness~* Blood transfusion within 4 weeks of study drug administration~* Inability to tolerate oral medication~* Positive hepatitis-B (HBV) surface antigen~* Positive hepatitis-C (HCV) antibody~* Any history or risk for tuberculosis (TB)~* Any major illness/condition or evidence of an unstable clinical condition~* Chest X-ray findings suspicious of infection at screening~* has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication~* Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first administration of study medication~* Has received Rituximab within 6 months of first administration of study medication~* Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication~* Any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BMS-986165 Dose 1 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 2 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 3 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 4 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 5 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- Placebo (Type: PLACEBO_COMPARATOR): Specified dose of Placebo for BMS-986165 on specified days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly found isolated distal deep vein thrombosis~* Patients complicated with active cancer~* Patients who are scheduled to be treated by anticoagulation therapy.~Exclusion Criteria:~* Patients with anticoagulation therapy for the index event before 10 days of allocation.~* Patient under anticoagulation therapy for the purpose of other than the index event.~* Patients with thrombolysis therapy or IVC filter at the Index event.~* Patients with creatinine clearance less than 30 ml/min.~* Patients who are expected to have a life prognosis of 3 months or less.~* Patients with pulmonary embolism.~* Patients who are not appropriate for the participation of the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12-month Edoxaban (Type: EXPERIMENTAL): Edoxaban for 12 months
- 3-month Edoxaban (Type: ACTIVE_COMPARATOR): Edoxaban for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ovarian germ cell tumors :~  1. 20 benign ( mature cystic teratoma ).~ 2. 22 malignant ones ( 5 dysgerminoma , 8 immature teratoma and 9 yolk sac tumor).~ 3. 20 Normal ovaries .~Exclusion Criteria:~1. Epithelial ovarian tumors~2. sex cord -stromal ovarian tumors.~3. metastatic ovarian lesions.

- Gender: FEMALE
- Minimum Age: 6 Months
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Malignant ovarian germ cell tumors ( MOGCTs). (Type: None): 22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
- Mature cystic teratomas. (Type: None): 20 cases of mature teratomas will be treated by anti P16 antibody .
- Normally apparent ovaries. (Type: None): 20 cases of normally apparent ovaries will be treated by anti P16 antibody .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronos: the Use of Chronobiological Treatment in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of major depression according to DSM-IV~* Patient with major depression as part of a bipolar disorder should be in adequate mood stabilizing therapy at entry to the study~* Age of 18 or above~* A score on the Hamilton Depression Scale, 17 items version of at least 18~Exclusion Criteria:~* Primary psychotic disorder~* Psychotic depression~* Drug or alcohol abuse~* Severe organic brain disease~* Severe suicidal ideation (a score of 2 or above on the Hamilton Depression Scale, 17-items version)~* Mental retardation~* Pregnancy or lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Sleep deprivation in combination with light and duloxetine
- B (Type: ACTIVE_COMPARATOR): Exercise and duloxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 and Therapy Study for Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. aged 7-14 years (boys and girls)~2. DSM-IV-TR diagnosis of major depressive disorder and/or dysthymic disorder as determined by consensus conference~3. Children's Depression Rating Scale (CDRS-R) score ≥ 40~4. full scale IQ ≥ 70~5. child and at least one parent must be able to complete all assessments~6. child must be able to swallow capsules (training in swallowing will be offered)~7. parent/guardian and child must be willing to have blood drawn from child at two study assessments.~Exclusion Criteria:~1. major medical disorders (eg diabetes, epilepsy, metabolic disorder)~2. inability to communicate in English~3. lack of access via phone~4. autism~5. schizophrenia, or other psychotic states warranting anti-psychotic medication~6. DSM-IV-TR diagnosis of a bipolar disorder~7. active suicidal concern (e.g., I want to kill myself, a plan for suicide, or an attempt in the past month; however, passive suicidal ideation, such as I wish I were dead would not exclude)~8. intake in the previous 4 weeks of supplemental Ω3 fatty acids.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Supplement and No PEP (Type: PLACEBO_COMPARATOR): Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
- Omega-3 and PEP (Type: EXPERIMENTAL): Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.
- Omega-3 and No PEP (Type: EXPERIMENTAL): Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
- Placebo Supplement and PEP (Type: EXPERIMENTAL): Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Must satisfy A and B and C and D below:~* (A) Women aged \> 55~* (B) Postmenopausal~* (C) Osteoporotic with high risk of fracture~Exclusion Criteria:~* Confirmed serum alkaline phosphatase above upper normal limit with no explanation~* Liver disease (AST or ALT \> 2 x upper normal limit).~* Renal disease (serum creatinine \> 2.0 mg/dl).~* Hypercalcemia (Ca \>10.5 mg/dL)~* Elevated blood PTH (intact PTH \> 65 pg/ml)~* Serum 25-OH vitamin D \< 20 ng/ml~* HCT \< 32%.~* History of malignancy (except basal cell carcinoma) or radiation therapy.~* Significant cardiopulmonary disease including unstable coronary artery disease, stage D ACC/AHA heart failure or any other condition that the investigator deems may preclude the subject from participating safely or completing the protocol procedures.~* Major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.~* Excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.~* Known congenital or acquired bone disease other than osteoporosis (including osteomalacia, hyperparathyroidism, Paget's disease)~* Current use or use in the past 6 months of oral bisphosphonate~* Current use or use within the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin.~* Use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months.~* Any current or previous use of strontium or any parenteral bisphosphonate.~* Known sensitivity to mammalian cell-derived drug products.~* Known sensitivity to teriparatide or any of its excipients.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denosumab ONLY (Type: EXPERIMENTAL): None
- teriparatide (Forteo®) ONLY (Type: EXPERIMENTAL): None
- denosumab and teriparatide (Forteo®) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Glaucoma or ocular hypertension in both eyes~* Currently being treated with latanoprost 0.005% QD~* IOP greater than or equal to 18mm Hg on latanoprost 0.005%~* Best-corrected VA of 20/200 or better in each eye~* Visual field within 6 months of study entry~Exclusion Criteria:~* Secondary glaucoma~* Active intraocular inflammation or macular edema~* Intraocular surgery or laser surgery within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Communicating Risk Information for Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Must be age 18 or older, active enrollees in the CPMC trial, and able to read and write in English.~Exclusion Criteria:~Individuals that do not meet the inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No risk feedback (Type: NO_INTERVENTION): No obesity risk information given (control)
- Genetic risk feedback (Type: EXPERIMENTAL): Only personal genetic risk information provided
- Lifestyle risk feedback (Type: EXPERIMENTAL): Only personal lifestyle risk information provided
- Both genetic or lifestyle risk feedback (Type: EXPERIMENTAL): Personal genetic and lifestyle information provided

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy postmenopausal women (45-80 years old) with a diagnosis of osteoporosis~Exclusion Criteria:~* Use of estrogen or hormone replacement therapy~* Use of bisphosphonates, strontium ranelate or denosumab~* Use of parathyroid analogues or other bone metabolic agents~* Medical conditions which might alter bone metabolism~* Any known clinically significant disease affecting calcium metabolism or history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia~* Impairment of thyroid function

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PTH analog tablet (Type: EXPERIMENTAL): PTH(1-31) 5 mg tablet, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching tablet, once daily
- Forsteo (Type: ACTIVE_COMPARATOR): Forsteo (teriparatide) 20 mcg SC Injection, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Written informed consent provided. Males or females aged ≥18 years. Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.~Stage IIIA N2 NSCLC according to the pathological evidence of endobronchial ultrasound(EBUS).~The biopsy specimen shows EGFR mutation in exon 19 or 21 by DNA sequencing. Measurable disease must be characterized according to RECIST criteria: measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥20cm with conventional techniques (PE, CT, XR, MRI) or as ≥ 10cm with spiral scan.~ECOG performance status 0-1. Life expectancy ≥12 weeks.~Female subjects should not be pregnant or breast-feeding.~Exclusion Criteria:~The biopsy specimen shows EGFR wildtype in exon 19 or 21 by DNA sequencing. Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).~Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy).~Known hypersensitivity to Tarceva or any of its recipients.~Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the subject at high risk for treatment-related complications.~Sexually active males and females(of childbearing potential) unwilling to practice contraception during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Single-arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete